HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines.

Abstract
Sensitivity of several human and mouse cancer cell lines to methylacetylenic putrescine (MAP) was evaluated using clonogenic, sulforhodamine B and cell counting assays. The effects of MAP on cell morphology, cell cycle phase distribution and changes in polyamine metabolism of xenografted MCF-7 and MDA-MB-231 human mammary tumor cells were also investigated. On the basis of IC50 values, BHT-101 human thyroid carcinoma cells were the most sensitive (9 micrograms/ml), followed by P388 mouse lymphoma (32 micrograms/ml), MCF-7 (48 micrograms/ml) and MDA-MB-231 (110 micrograms/ml) human breast carcinoma cell lines. MAP treatment led to accumulation of P388 cells in G1 phase. At higher doses, the cytoplasm of the cells became vacuolated followed by apoptosis. The foamy cytoplasm may suggest a rare type of cell death (Clarke III type) called non-apoptotic programmed cell death. MAP treatment resulted in a total inhibition of ornithine decarboxylase (ODC) activity with a concomitant decrease of intracellular polyamine (mostly putrescine and spermidine) content in the breast cancer cells, whilst the spermine concentration was shown to increase. MAP proved at least 10 times more potent than the formerly studied DL-alpha-difluoromethylornithine making it an attractive candidate for clinical testing.
AuthorsI Pályi, T Kremmer, A Kálnay, G Turi, R Mihalik, K Bencsik, M Boldizsár
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 10 Issue 1 Pg. 103-11 (Jan 1999) ISSN: 0959-4973 [Print] England
PMID10194553 (Publication Type: Journal Article)
Chemical References
  • Alkynes
  • Antineoplastic Agents
  • Diamines
  • Ornithine Decarboxylase Inhibitors
  • Polyamines
  • 6-heptyne-2,5-diamine
  • Ornithine Decarboxylase
Topics
  • Alkynes
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Breast Neoplasms (drug therapy, metabolism, pathology)
  • Cell Cycle (drug effects)
  • Cell Death (drug effects)
  • Cell Division (drug effects)
  • Cell Survival (drug effects)
  • Diamines (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Inhibitory Concentration 50
  • Leukemia P388 (drug therapy, metabolism, pathology)
  • Male
  • Mice
  • Ornithine Decarboxylase (metabolism)
  • Ornithine Decarboxylase Inhibitors
  • Polyamines (metabolism)
  • Prostatic Neoplasms (drug therapy, pathology)
  • Thyroid Neoplasms (drug therapy, metabolism, pathology)
  • Tumor Cells, Cultured (drug effects, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: